The DAPA-HF trial showed a 26% reduction in the primary endpoint of CV mortality and HHF or urgent HF visits in patients with LVEF ≤ 40% and high BNP/NT-proBNP, regardless of the diabetic status. This evidence concerns the gene NPPB and hydrops fetalis.